Compare STRIDES PHARMA SCIENCE with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs GSK PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE GSK PHARMA STRIDES PHARMA SCIENCE/
GSK PHARMA
 
P/E (TTM) x 7.8 31.8 24.6% View Chart
P/BV x 0.9 12.6 7.4% View Chart
Dividend Yield % 0.5 1.3 41.4%  

Financials

 STRIDES PHARMA SCIENCE   GSK PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
GSK PHARMA
Mar-19
STRIDES PHARMA SCIENCE/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1473,595 31.9%   
Low Rs6421,253 51.2%   
Sales per share (Unadj.) Rs317.2184.7 171.8%  
Earnings per share (Unadj.) Rs7.826.3 29.8%  
Cash flow per share (Unadj.) Rs25.129.2 85.9%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.20.8 27.1%  
Book value per share (Unadj.) Rs274.3126.3 217.1%  
Shares outstanding (eoy) m89.50169.40 52.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.813.1 21.5%   
Avg P/E ratio x114.092.2 123.7%  
P/CF ratio (eoy) x35.783.1 42.9%  
Price / Book Value ratio x3.319.2 17.0%  
Dividend payout %25.576.1 33.5%   
Avg Mkt Cap Rs m80,058410,626 19.5%   
No. of employees `0002.55.0 50.5%   
Total wages/salary Rs m4,3415,372 80.8%   
Avg. sales/employee Rs Th11,325.86,306.7 179.6%   
Avg. wages/employee Rs Th1,731.41,083.1 159.9%   
Avg. net profit/employee Rs Th280.1898.0 31.2%   
INCOME DATA
Net Sales Rs m28,39431,281 90.8%  
Other income Rs m9411,023 91.9%   
Total revenues Rs m29,33432,304 90.8%   
Gross profit Rs m3,9656,009 66.0%  
Depreciation Rs m1,540486 317.0%   
Interest Rs m1,9626 32,706.7%   
Profit before tax Rs m1,4036,540 21.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436287 -151.8%   
Tax Rs m972,373 4.1%   
Profit after tax Rs m7024,454 15.8%  
Gross profit margin %14.019.2 72.7%  
Effective tax rate %6.936.3 19.1%   
Net profit margin %2.514.2 17.4%  
BALANCE SHEET DATA
Current assets Rs m24,83620,061 123.8%   
Current liabilities Rs m18,99314,543 130.6%   
Net working cap to sales %20.617.6 116.7%  
Current ratio x1.31.4 94.8%  
Inventory Days Days7157 125.0%  
Debtors Days Days11314 806.5%  
Net fixed assets Rs m34,28914,343 239.1%   
Share capital Rs m8951,694 52.8%   
"Free" reserves Rs m23,65119,704 120.0%   
Net worth Rs m24,54621,398 114.7%   
Long term debt Rs m15,5132 775,660.0%   
Total assets Rs m65,43739,113 167.3%  
Interest coverage x1.71,091.0 0.2%   
Debt to equity ratio x0.60 676,202.6%  
Sales to assets ratio x0.40.8 54.3%   
Return on assets %4.111.4 35.7%  
Return on equity %2.920.8 13.7%  
Return on capital %6.931.9 21.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,697534 2,939.5%   
Fx outflow Rs m7357,091 10.4%   
Net fx Rs m14,962-6,557 -228.2%   
CASH FLOW
From Operations Rs m1,8713,994 46.8%  
From Investments Rs m5,826-1,433 -406.4%  
From Financial Activity Rs m-10,157-3,584 283.4%  
Net Cashflow Rs m-2,615-1,023 255.6%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 37.8 10.2 370.6%  
FIIs % 8.6 23.8 36.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 15.4 168.2%  
Shareholders   56,241 102,036 55.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Higher; IT and Banking Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended higher. Benchmark Indices were highly volatile swinging between positive and negative territory.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Nov 14, 2019 03:37 PM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - VENUS REMEDIES COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS